CYT006-AngQb
a virus-shaped noninfectious particle that is chemically coupled with angiotensin II, an octapeptide vasoconstrictor which induces the body to produce antibodies against this small molecule to minimize its effects on constricting blood vessels
Networked:
3
relevant articles (
0 outcomes,
1 trials/studies)
for this Bio-Agent,
Comments
Bio-Agent Context: Research Results
Experts
| 1. | Maurer, Patrik:
2 articles
(01/2010 - 03/2008)
|
| 2. | Bachmann, Martin F:
2 articles
(01/2010 - 03/2008)
|
| 3. | Quan, Wu Yong:
1 article
(05/2009)
|
| 4. | Pandey, Rabindra:
1 article
(05/2009)
|
| 5. | Jie, Su Li:
1 article
(05/2009)
|
| 6. | Hong, Fang:
1 article
(05/2009)
|
| 7. | Wagner, Frank:
1 article
(03/2008)
|
| 8. | Volk, Hans-Dieter:
1 article
(03/2008)
|
| 9. | Tissot, Alain C:
1 article
(03/2008)
|
| 10. | Stocker, Hans:
1 article
(03/2008)
|
Related Diseases
| 1. | Hypertension (High Blood Pressure)
01/01/2010
- " Administration of CYT006-AngQb to subjects with mild to moderate hypertension was safe and well tolerated. " 03/08/2008
- " METHODS: In this multicentre, double-blind, randomised, placebo-controlled phase IIa trial, 72 patients with mild-to-moderate hypertension were randomly assigned with a computer-generated randomisation list to receive subcutaneous injections of either 100 mug CYT006-AngQb (n=24), 300 mug CYT006-AngQb (24), or placebo (24), at weeks 0, 4, and 12. " 05/15/2009
- " More recently, immunization against angiotensin-I with PMD-3117 vaccine, angiotensin-II with CYT006-AngQb vaccine and targeting angiotensin-II type 1A receptor with ATR12181 vaccine have provided optimism in the development of a hypertension vaccine. "
Order ALL the reference details at left...
|
|
Related Drugs and Biologics
Related Therapies and Procedures